Long-term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open-label extension study.
about
Tight controlled dose reduction of biologics in psoriasis patients with low disease activity: a randomized pragmatic non-inferiority trial.Sustained PASI, DLQI and EQ-5D response of biological treatment in psoriasis: 10 years of real-world data in the Swedish National Psoriasis Register.Effect of tofacitinib withdrawal and re-treatment on patient-reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis.Biological therapies for psoriasis.Statistical reporting in randomized controlled trials from the dermatology literature: a review of 44 dermatology journals.Adalimumab: A Review in Chronic Plaque Psoriasis.Clinical studies in dermatology require a post-treatment observation phase to define the impact of the intervention on the natural history of the complaint.Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis.1(st) French-Israeli International Conference on B Cells and therapeutic antibodies: October 23-25, 2011 Jerusalem, Israel.Efficacy and safety of adalimumab in psoriatic patients previously treated with etanercept in a real-world setting.Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.The impact of biologic agents on health-related quality of life outcomes in patients with psoriasis.Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial.Adalimumab retreatment successfully restores clinical response and health-related quality of life in patients with moderate to severe psoriasis who undergo therapy interruption.Psoriasis treatment with adalimumab in clinical practice: long-term experience in a center for biological therapy in the Czech Republic.Quo vadis, biological treatment for psoriasis and psoriatic arthritis?
P2860
Q33651502-AF842128-B63F-48B7-B611-C7F1DC7233C5Q36413344-894A25F9-9E71-4406-933E-5FE16F621FE7Q37631750-313BF97B-5BD6-4D14-89AE-1F5CCD55D3C2Q38155648-28149019-EBB9-4A25-BBB1-B102DC7A7894Q38491401-54431ACC-1687-4C4C-AF3D-C0FEECD5F235Q38639495-46868F32-315D-4EE8-A036-C3739093A9F0Q38792733-C732CEAE-1CE5-4E08-B743-85D0B9085E25Q38965214-A46A3B8B-5A9A-449F-86EC-6D03CB37D972Q42333451-8950FD05-0650-4632-BE7D-9364849738B6Q46735206-68180A93-9F47-4C91-8843-83747A5F00D1Q47260366-7FA7D64D-EEB6-4DF0-9749-2FE4E5ED8FFAQ47644680-D1E06D63-EE6C-471F-AE52-08DCD4615BF4Q48059175-98C5356B-D8A5-4AB6-B143-FACA9100E59BQ48063769-1072C13C-8268-422D-A69A-836C508F4463Q48298598-2B396E99-FD39-4EB7-9894-BD8571EBA1F6Q55687055-1E147303-0F9F-4D26-83E4-3B5E24016AC0
P2860
Long-term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open-label extension study.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Long-term outcomes of interrup ...... he open-label extension study.
@en
Long-term outcomes of interrup ...... he open-label extension study.
@nl
type
label
Long-term outcomes of interrup ...... he open-label extension study.
@en
Long-term outcomes of interrup ...... he open-label extension study.
@nl
prefLabel
Long-term outcomes of interrup ...... he open-label extension study.
@en
Long-term outcomes of interrup ...... he open-label extension study.
@nl
P2093
P2860
P1476
Long-term outcomes of interrup ...... the open-label extension study
@en
P2093
P2860
P304
P356
10.1111/J.1468-3083.2012.04515.X
P50
P577
2012-03-16T00:00:00Z